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Abstract
Purpose: The aim of this study was to evaluate dosimetric differences between pencil beam convolution (PBC) algorithm and
anisotropic analytical algorithm (AAA) calculations in patients with lung and esophageal cancers. Methods: The existing plans
calculated with PBC for 60 patients treated in 2012 were recalculated with AAA maintaining the same beam geometry and dose
monitor units.  For these plans, dose prescription ranges were 41.4 Gy to 56.0 Gy for esophageal cancers and 50.0 Gy to 64.0
Gy for lung cancers. Dosimetric variables were the 95% PTV coverage, mean PTV dose, maximum spinal cord dose, lung V5Gy,
and lung V20Gy. Results: The 95% PTV coverage’s for both lung and esophageal tumors were reduced when recalculated with
AAA. Maximum spinal cord doses for lung cancer patients were reduced by 0.7 Gy and by 0.3 Gy for esophageal cancer patients
on AAA. On the other hand, lung V5Gy had 3.5% increase for both lung and esophageal cancer patients on AAA, whereas lung
V20Gy increased by 1.5% also on AAA for esophageal cancer patients. Conclusion: These clinical results confirm the differences
between AAA and PBC algorithms as observed in phantom dosimetric studies, and give an indication of the clinical implica-
tions of changing from one calculation algorithm to another.
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Introduction
Radical radiotherapy requires the calculated absorbed dose to
be delivered accurately in order to achieve tumor control.1, 2
In terms of treatment planning calculations; uncertainty in
the dose calculation should therefore be kept to a minimum
in order to achieve this maximal tumor control. The lung
being a heterogeneous tissue creates difficulties in this re-
gard.3 With the exception of Monte-Carlo simulation, which
has been shown to be closest to reality for dose calculation
and distribution, other treatment planning algorithms such
as Pencil Beam Convolution (PBC), Collapsed Cone and An-
isotropic Analytical Algorithm (AAA) may not be that accu-
rate.4 However, due to long calculation time with Mon-
te-Carlo makes it impracticable to be used routinely in the
current treatment planning systems.4
The PBC as documented in earlier findings performs poorly
in calculating dose to tumors in and around the lungs.5-7 It
does its calculations of dose distributions along a ray of line
from the beam source (pencil beam).8 To account for differ-
ences in attenuation, there are corrections to each pencil
beam that are obtained by a correction factor.9 These correc-
tions are done in terms of calculation with respect to a
point.9 The dose from the adjacent pencil beams is left out in
the calculation leading to inconsistencies in dose determina-
tion of large tumors in homogeneities.10
Corresponding author: Emmanuel Amankwaa-Frempong; Direc-
torate of oncology, Komfo Anokye Teaching Hospital, P.O. BOX
KS 1934, Kumasi, Ghana.
Cite this article as:
Amankwaa-Frempong E, Vernimmen F, Blay S, Ezhilalan R. Irra-
diation of lung and esophagus tumors: A comparison of dose dis-
tributions calculated by anisotropic analytical algorithm and pen-
cil beam convolution algorithm, a retrospective dosimetric study.
Int J Cancer Ther Oncol 2014; 2(2):020210.
DOI: 10.14319/ijcto.0202.10
2 Amankwaa-Frempong et al.: AAA and PBC comparison for lung and esophageal tumors International Journal of Cancer Therapy and Oncology
www.ijcto.org
Copyright © Amankwaa-Frempong et al. ISSN 2330-4049
The development of a superposition-convolution method
known as AAA, has been shown to be more than accurate
than PBC in photon dose calculations.11, 12 Because the AAA
algorithm takes into account lateral scattering it calculates
photon beams interactions in regions of complex tissue het-
erogeneities better.13The AAA is known to be faster (reduces
computational times). This algorithm has been incorporated
in the Eclipse (Varian Medical Systems, Palo Alto, CA) inte-
grated treatment planning system (TPS).14
The radiotherapy department of the Cork University Hospi-
tal (CUH) in the Republic of Ireland has been using Pencil
Beam Convolution for the 3D-planning. Recently, as part of
the implementation of intensity modulated radiation therapy
(IMRT), the planning system was upgraded in order to use
the AAA for dose calculations. In this study, we have per-
formed a dosimetric comparison of PBC versus AAA dose
calculations for a cohort of lung and esophageal cancer pa-
tients treated within the period of January-December, 2012.
This study was approved by the ethical committee of CUH.
Methods and Materials
Patients: The department in CUH renders a radiotherapy
service to a wide spectrum of cancer patients in Cork and the
surrounding counties of Kerry, Waterford and South Tip-
perary. The department works in close collaboration with
the departments of surgery, medical oncology, hematology,
histopathology and radiology. A total of 237 lung and
esophageal cancer patients were seen and treated during the
period from January to December 2012. Of these, 60 patients
were treated with radical intent for localized disease, with 31
lung cancer patients and 29 esophageal cancer patients. This
study population consisted of 23 females and 38 males with
respective age ranges of 50 - 86 years and 51 - 84 years.
CT Simulation: The CT scanner used for simulation was a
Siemens Somatom sensation, 40-slice helical scanner. Slice
thickness was 3 mm. Scans were obtained from the cricoid
cartilage to the superior aspect of the L2 vertebra. Patients
were positioned supine with arms immobilized above the
head and their legs on a knee support.
Treatment plans: The software within our treatment plan-
ning system is Eclipse version 11.0, calculation grid size 2.5
mm. For lung tumors gross tumor volume (GTV) was grown
isotropically by 8 mm to produce the clinical target volume
(CTV), and then edited taking into account likely patterns of
spread to create the final CTV. Margins of 7 mm axially and
12 mm longitudinally are added to create the planning target
volume (PTV). For esophageal cancers expanding the GTV
by 2 cm longitudinally and 1 cm axially produced a CTV.
The superior and inferior slices were edited. The CTV was
grown isotropically by 5 mm axially and 10 mm superior
inferiorly to produce the PTV. The existing PBC treatment
plans for the 60 lung and esophageal cases were retrieved.
These plans used beam energies of 6 MV and 15 MV. Dose to
the normalization point ranged from 41.4 Gy to 56.0 Gy for
esophageal cancers and 50.0 Gy to 64.0 Gy for lung cancers.
On the average two posterior oblique beams and one anteri-
or beam arrangement was used for esophageal cancers.
Three-field conformal plan was used for lung cancers and
contralateral lung beams were avoided. For each patient,
using the same beam configuration and original dose monitor
units, dose distributions were recalculated with AAA. The
following dosimetric variables were recorded: 95% PTV
coverage, maximum dose to PTV, mean dose to PTV, volume
of lung covered by 5 Gy dose of radiation (V5Gy) of lung,
volume of lung covered by 20 Gy dose of radiation (V20Gy) of
lung, and maximum spinal cord dose. All the lung volumes
excluded the PTV.
Analysis: Statistical analysis was performed using STATA
version 10. Wilcoxon signed-rank test was used to determine
the difference between PBC and AAA. When the p-value
was less than 0.05 the difference was deemed significant.
Results
Planning Target Volume: In this study, PTV volume ranged
from 64.2 cm3 to 954.4 cm3. For lung tumors from (Table 1)
the maximum and mean doses to the PTV as calculated with
AAA were all lower as compared to PBC dose calculations.
With a respective difference of 1.2 Gy (p < 0.001) and 2.2 Gy
(P < 0.03) observed. The 95% PTV coverage was also lower
(84.5%) with AAA, with a difference of the median values of
10.5% as compared to PBC (p < 0.001).
For esophageal tumors from (Table 2), the maximum and
mean doses to the PTV on AAA are also significantly (p <
0.001) lower although these differences are small compared
to the lung values (0.5 Gy and 0.4 Gy, respectively). The 95%
PTV coverage was 89.5% with AAA with a difference for the
median 95% PTV coverage of 5.5 % (p < 0.001).
Organs at risk: For lung cancer patients, (Table 3), the max-
imum spinal cord doses, although within clinical tolerance
for the two algorithms, were significantly different with
values 42.8 Gy and 42.1 Gy for PBC and AAA, respectively
(p = 0.003). The lung V5Gy was 42.5% for PBC and 46.0% for
AAA, (p < 0.001). Lung V20Gy was 21.0% for both AAA and
PBC. For esophageal cancer patients, (Table 4), the maxi-
mum spinal cord dose was 29.1 Gy on PBC and 28.8 Gy on
AAA (p = 0.002). The lung V5Gy were 45% and 48.5% on PBC
and AAA, respectively (p < 0.001). The lung V20Gy recorded
18.5% and 19.0% for PBC and AAA, respectively.
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FIG. 1: Comparison of dose volume histograms (DVHs) for AAA and PBC
TABLE 1: Maximum and mean doses to PTV (in Gy) as well as 95% PTV coverage (in percentage) for 31 lung cancer patients.
Parameter PBC AAA p value
Maximum dose PTV (Gy) 63.3(59-64.4) 62.1(58-63.9) <0.001
95% PTV coverage (%) 95(95-95) 84.5(81.2-86.3) <0.001
Mean PTV dose (Gy) 60.2(56.0-60.3) 58.0(53.9-58.7) <0.001
TABLE 2: Maximum and mean doses to PTV (in Gy) as well as 95% coverage (in percentage) for 29 esophageal cancer patients.
Parameter PBC AAA p value
Maximum dose PTV (Gy) 44.3(43.8-54.4) 43.8(43.3-53.2) <0.001
95% PTV coverage (%) 95(95-95) 89.5(88.1-90.8) <0.001
Mean PTV dose (Gy) 41.6(41.5-50.8) 41.2(40.9-50.0) <0.001
FIG. 2: Dose color wash for the AAA (right) and PBC (left).
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TABLE 3: Maximum dose to the cord, V5Gy, and V20Gy calculated on PBC and AAA plans for 31 lung cancer patients.
Parameter PBC AAA P value
Maximum cord dose (Gy) 42.8(22.8-44.8) 42.1(29-44.5) 0.003
Lung V20Gy (%) 21.0(15.0-27.5) 21.0(15.0-27.5) 0.405
Lung V5Gy (%) 42.5(31.0-52.5) 46.0(35.0-52.5) <0.001
TABLE 4: Maximum dose to the cord, V5Gy, and V20Gy calculated on PBC and AAA plans for 29 esophageal cancer patients.
Parameter PBC AAA P value
Maximum cord dose (Gy) 29.1(22.1-33.4) 28.8(22.1-33.0) 0.002
Lung V20Gy (%) 18.5(11.2-27.5) 19.0(11.0-26.2) 0.008
Lung V5Gy (%) 45.0(33.7-52.5) 48.5(38.0-57.5) <0.001
Discussion
Several studies have shown that in conventional 3-D plan-
ning AAA calculates dose distributions in a heterogeneous
medium more accurately than PBC. Gagne and Zavgorodni 15
demonstrated this in the vertical water-lung interface phan-
tom.15 Fogliata et al. also found that AAA calculations were
satisfactory in terms of reproducing measured data for open
and wedged beams as compared with PBC.16 In using a
phantom, Cranmer-Sargison et al. 17 was able to demonstrate
an over-prediction of the dose to the lung portion of the
phantom for AAA calculations. Carrasco et al. 18, in compar-
ing dose calculation algorithms in phantom with lung equiv-
alent heterogeneities under conditions of lateral disequilib-
rium, showed that AAA was better for calculations in the
lungs.
This study showed an over-estimation by PBC in calculating
dose to lung and esophageal PTV’s of 10.5% for lung tumors
and 5.5% for esophageal tumors compared to AAA. This
finding is consistent with the investigation of Ronde and
Hoffman 19, in which PBC overestimated the lung dose by 6 -
10%.19 Herman et al 20, in evaluating PBC and AAA in lung
irradiation also found a 10% over estimation of dose to the
PTV by PBC. In that study, 20 treatment plans from PBC
were recalculated with AAA, retaining identical beam ar-
rangements, photon beam fluencies and dose monitor units.
The PBC plans designed to give 60 Gy, delivered 51.6 Gy
when re-calculated with the AAA corresponding to 14%
overestimation.20 In another study by Ueki et al. 21,
eighty-three patients with non-small-cell lung cancer
(NSCLC) underwent stereotactic body radiation therapy
(SBRT). AAA and PBC were compared to evaluate the
dose-volume parameters under different heterogeneity cor-
rections. The 95% PTV coverage for PBC was 7% higher
than AAA. Xiao et al. 22 in the RTOG 0236 protocol evaluat-
ed twenty patients, comparing PBC plans after recalculating
them on AAA, and showed a decrease of 10% in the cover-
age of the 95% volume of the PTV.22
The radio therapeutic management of cancers has to strike a
balance between sufficient dose to the target volume in or-
der to get a cure on the one hand and a safe dose to the or-
gans at risk on the other hand. Although the dose to the
spinal cord in this study was different, both dose levels were
clinically safe. AAA calculations underestimated the spinal
cord dose for esophageal tumors and for lung cancer, by
1.0% and 1.6% between the two algorithms respectively, but
both remained within clinical tolerance. Ronde and Hoff-
man, who compared AAA and PBC treatment plans in lung
geometry found that AAA underestimated the spinal cord
dose by as much as 7%.19 In another study, however, com-
paring Monte Carlo simulation and AAA, the AAA was ob-
served to overestimate the spinal cord dose by only 0.2%.23
These findings are re-assuring in terms of doses to the spinal
cord all remaining within clinical tolerance.
In terms of the lung radiation tolerance parameters (V5Gy and
V20Gy) we observed no differences between PBC and AAA for
lung V20Gy (21.0%), in both esophageal and lung cancers. The
difference in integral lung dose is reflected in the difference
of the V5Gy values between AAA and PBC. This difference
increases slightly for increasing volumes of PTV’s (Figure 1),
with V5Gy recordings showing a 3.5% difference for lung and
esophageal cancers between PBC and AAA, all been highest
with AAA. The V5Gy (46%) and V20Gy (21%) is consistent
with findings of Kroon et al. 24, who had 46.6% and 19.3%
for V5Gy and V20Gy, respectively for lung tumors also calcu-
lated on AAA.24 The difference in mean PTV doses between
PBC and AAA for lung and esophageal cancers were 4% and
1%, respectively. Fotina et al. 25 in comparing collapsed cone
and Monte-Carlo algorithm observed less than 3% difference
between the two algorithms. The Acuros XB calculation
algorithm for photon beams has been shown to be more ac-
curate than AAA 26-28, and it has also been observed to have a
relatively lower PTV dose as compared to AAA ranging from
2 - 4%.26 This shows that there is not much difference be-
tween the algorithms in terms of mean PTV dose. Therefore,
based on mean PTV doses, tumor control may be similar
irrespective of the algorithm used. However, caution is war-
ranted when treating lung tumors especially when the PTV
volume is large and high energy beams are used.
Conclusion
The results from our study have shown that the differences
reported in other studies with AAA and PBC algorithm in
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terms of PTV coverage and organs at risk also occurred in
our study population of a random group of esophageal and
lung cancer patients. To avoid overestimation, it is recom-
mended to use the AAA algorithm in the treatment planning
instead of PBC, especially for the lung tumors. In adopting
AAA as a new algorithm into a clinical treatment planning
practice, a good understanding of the effects and potential
consequences by oncologists is important.
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